Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Optimer Spells Out Plans For Further Dificid Penetration

This article was originally published in The Pink Sheet Daily

Executive Summary

Optimer Pharmaceuticals outlined its commercial strategy for recently launched antibiotic Dificid. The company plans to concentrate on long-term care facilities and proving that the drug is preferable over potential generic competition.

You may also be interested in...

Optimer’s Dificid Could Pave A Path To Higher Prices For Antibiotics

The drug developer appears to be making the case for premium pricing by differentiating fidaxomicin for its ability to sustain clinical response and cut costs associated with recurrence.

Optimer's Early Sales Of Dificid Topping Analyst Projections

The anti-clostridial antibiotic, approved by FDA in May, is seeing rapid early adoption by hospital formularies.

Optimer Looking At Prophylaxis As Next Frontier For C. Difficile Agent Dificid

Optimer's next step, having garnered the expected FDA approval of its Clostridium difficile antibiotic Dificid (fidaxomicin), will be to consider prophylaxis as a possible road to an expanded market for the macrolide antibiotic.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts